Sandbox Reserved 1105: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 82: | Line 82: | ||
[[Image: Drugstructure.png | thumb | left | alt=Puzzle globe| Structures of thyroxine (T4), the natural ligand of TTR and other designed TTR fibril formation inhibitors| 200 px]] | [[Image: Drugstructure.png | thumb | left | alt=Puzzle globe| Structures of thyroxine (T4), the natural ligand of TTR and other designed TTR fibril formation inhibitors| 200 px]] | ||
Drug research is | Drug research is based on the inhibition of amyloidogenic TTR by stabilization of native tetrameric conformation, using binding ligands to prevent TTR dissociation. | ||
The fibril formation inhibitors studied are ligands that resemble to the natural ligand T4 but more efficient in binding TTR, leading to a decrease of the amyloidogenic potential. The first potent amyloid inhibitors developed were non-steroidal anti-inflammatory drugs (NSAID), such as flufenamic acid ([[1bm7]]), diclofenac ([[1dvx]]), flurbiprofen ([[1dvt]]), indomethacin, diflunisal, meclofenamic acid, mefenamic acid, or fenoprofen. | The fibril formation inhibitors studied are ligands that resemble to the natural ligand T4 but more efficient in binding TTR, leading to a decrease of the amyloidogenic potential. The first potent amyloid inhibitors developed were non-steroidal anti-inflammatory drugs (NSAID), such as flufenamic acid ([[1bm7]]), diclofenac ([[1dvx]]), flurbiprofen ([[1dvt]]), indomethacin, diflunisal, meclofenamic acid, mefenamic acid, or fenoprofen. | ||
